High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

This study is ongoing, but not recruiting participants.

Sponsored by:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00186238

Purpose

To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.

Condition	Intervention	Phase
Multiple Myeloma	Procedure: high dose chemotherapy then autologous hematopoietic cell transplant	Phase II

Genetics Home Reference related topics: aceruloplasminemia hemophilia

MedlinePlus related topics: Multiple Myeloma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

Further study details as provided by Stanford University:

Primary Outcome Measures:

Toxicity and efficacy of sequentially administered high dose chemotherapy and autologous hematopoietic cell transplantation

Estimated Enrollment:	300
Study Start Date:	September 1994

Detailed Description:

To assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide and VP-16 followed by total body irradiation or BCNU and high dose mephalan and autologous stem cell rescue in the treatment of multiple myeloma.

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:- received cytoreduction prior to transplant

adequate organ function
 Exclusion Criteria:- previous transplant
smoldering MM or benign monoclonal gammopathy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186238

Locations

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

Sally Arai

Stanford University

More Information

Study ID Numbers:	BMT27, 73217, BMT27, NCT00186238
Study First Received:	September 13, 2005
Last Updated:	October 3, 2008
ClinicalTrials.gov Identifier:	NCT00186238
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Immunoproliferative Disorders
Hemorrhagic Disorders
Multiple myeloma
Hematologic Diseases
Blood Protein Disorders
Blood Coagulation Disorders

Vascular Diseases
Paraproteinemias
Lymphoproliferative Disorders
Hemostatic Disorders
Neoplasms, Plasma Cell
Multiple Myeloma

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type
Immune System Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 15, 2009